SEC-sourced researchBeta
INO
INOVIO PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0001055726
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 12, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 217,756.0000 | Mar 12, 2026 |
| December 2025 | 65,343.0000 | Mar 12, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 65,343.0000 | -84,945,901.0000 | -88,629,430.0000 | 74,310,035.0000 | 50,213,759.0000 | Mar 12, 2026 |
| December 2024 | 217,756.0000 | -107,254,126.0000 | -104,076,553.0000 | 113,197,206.0000 | 44,693,411.0000 | Mar 12, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $65.34K | December 2025 | Mar 12, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $217.76K | December 2024 | Mar 12, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$84.95M | December 2025 | Mar 12, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$88.63M | December 2025 | Mar 12, 2026 | 10-K |
| Total assetsAssets | $74.31M | December 2025 | Mar 12, 2026 | 10-K |
| Total liabilitiesLiabilities | $50.21M | December 2025 | Mar 12, 2026 | 10-K |